A D Norden

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA, 02115, USA
    J Neurooncol 121:297-302. 2015
  2. doi request reprint Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
  3. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
  4. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
  5. doi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
  6. doi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
  7. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
  8. ncbi request reprint A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG)
    J Drappatz
    Dana Farber Cancer Institute, Boston, MA Northwestern University, Feinberg School of Medicine, Chicago, IL University of Virginia Medical Center, Charlottesville, VA Massachusetts General Hospital, Boston, MA Novartis Pharmaceuticals, East Hanover, NJ
    J Clin Oncol 29:2050. 2011
  9. ncbi request reprint Phase II study of dose-intense temozolomide in recurrent glioblastoma
    S Hammond
    Dana Farber Cancer Institute, Boston, MA Wake Forest University School of Medicine, Winston Salem, NC Darthmouth Hitchcock Medical Center, Lebanon, NH Massachusetts General Hospital, Boston, MA Massachusetts General Hospital Cancer Center, Boston, MA University of Pennsylvania, Philadelphia, PA
    J Clin Oncol 29:2038. 2011
  10. doi request reprint Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012

Collaborators

Detail Information

Publications15

  1. doi request reprint Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA, 02115, USA
    J Neurooncol 121:297-302. 2015
    ..6 months (1.0-6.9). Among AG patients in each arm, PFS6 was 0 %. Treatment was well tolerated. In conclusion, nintedanib is not active against recurrent high-grade glioma, regardless of prior bevacizumab therapy...
  2. doi request reprint Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
    ..At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor...
  3. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
    ..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints...
  4. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
    ..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy...
  5. doi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
    ..Normalisation of dilated and leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radiation therapy and cytotoxic chemotherapy...
  6. doi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
    ..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies...
  7. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  8. ncbi request reprint A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG)
    J Drappatz
    Dana Farber Cancer Institute, Boston, MA Northwestern University, Feinberg School of Medicine, Chicago, IL University of Virginia Medical Center, Charlottesville, VA Massachusetts General Hospital, Boston, MA Novartis Pharmaceuticals, East Hanover, NJ
    J Clin Oncol 29:2050. 2011
    ..We conducted a phase I study to determine the safety and toxicity when combining panobinostat with bevacizumab in recurrent HGG...
  9. ncbi request reprint Phase II study of dose-intense temozolomide in recurrent glioblastoma
    S Hammond
    Dana Farber Cancer Institute, Boston, MA Wake Forest University School of Medicine, Winston Salem, NC Darthmouth Hitchcock Medical Center, Lebanon, NH Massachusetts General Hospital, Boston, MA Massachusetts General Hospital Cancer Center, Boston, MA University of Pennsylvania, Philadelphia, PA
    J Clin Oncol 29:2038. 2011
    ..Since MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance in patients with recurrent GBM...
  10. doi request reprint Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012
    ..The recommended doses for further study are oral panobinostat 30 mg three times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. A phase II clinical trial in recurrent HGG is underway...
  11. ncbi request reprint Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM)
    E C Quant
    Dana Farber Cancer Institute, Boston, MA Massachusetts General Hospital, Boston, MA Memorial Sloan Kettering Cancer Center, New York, NY University of Virginia Medical Center, Charlottesville, VA Beth Israel Deaconess Medical Center, Boston, MA Henry Ford Health System, Detroit, MI Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA Massachusetts General Hospital Cancer Center, Boston, MA
    J Clin Oncol 29:2069. 2011
    ..We conducted a phase II study of vandetanib in patients with newly-diagnosed GBM in combination with radiation (RT) and temozolomide (TMZ)...
  12. ncbi request reprint Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma
    J Drappatz
    Dana Farber Cancer Institute, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Memorial Sloan Kettering Cancer Center, New York, NY University of Virginia, Charlottesville, VA Dana Farber Cancer Institute Brigham and Women s Cancer Center, Boston, MA
    J Clin Oncol 27:2031. 2009
    ..We conducted a phase I study of vandetanib, an inhibitor of VEGFR2 and EGFR, in patients with newly-diagnosed GBM in combination with RT and temozolomide (TMZ)...
  13. ncbi request reprint Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen
    E Quant
    Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 26:2008. 2008
    ..Patients who progress on this regimen are frequently maintained on bevacizumab and the concurrent chemotherapeutic agent is changed. The benefit of this therapeutic strategy is unknown...
  14. doi request reprint Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C Lu-Emerson
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney Street, SW 430, Boston, MA 02115, USA
    J Neurooncol 104:287-91. 2011
    ..Treatment was moderately well-tolerated, although one patient sustained a grade 4 intracerebral hemorrhage. Dasatinib in conjunction with bevacizumab does not appear to have activity in patients with recurrent, heavily pretreated GBM...
  15. ncbi request reprint Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
    A D Norden
    Dana Farber Cancer Institute, Boston, MA Neuro Oncology Program, Cedars Sinai Medical Center, Los Angeles, CA Duke University Medical Center, Durham, NC Beth Israel Deaconess Medical Center, Boston, MA Massachusetts General Hospital Cancer Center, Boston, MA Wake Forest University School of Medicine, Winston Salem, NC Northwestern University, Feinberg School of Medicine, Chicago, IL Massachusetts General Hospital, Boston, MA Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:2040. 2011
    ..The somatostatin analog octreotide had promising results in a pilot clinical study. Pasireotide LAR is a long-acting somatostatin analog that has higher binding affinity for most somatostatin receptor subtypes than octreotide...